The National Institute of Allergy and Infectious Diseases (NIAID) offers the Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19) grant. This program translates innovative HIV vaccine concepts from basic science to initial human clinical trials. It provides support for advancing basic science, determining clinical feasibility, and conducting the initial human clinical study. Specifically, it assists in preclinical development, regulatory compliance, manufacturing, and safety testing to enable human trials. Preclinical-only projects are not eligible. NIAID anticipates approximately $3.2 million for 1-2 awards.
Opportunity ID: 53329
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-10-161 |
| Funding Opportunity Title: | Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.855 — Allergy, Immunology and Transplantation Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 3 |
| Posted Date: | Mar 30, 2010 |
| Last Updated Date: | Apr 19, 2011 |
| Original Closing Date for Applications: | Aug 02, 2012 |
| Current Closing Date for Applications: | Nov 08, 2011 |
| Archive Date: | Dec 08, 2011 |
| Estimated Total Program Funding: | $3,200,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Independent school districts County governments Private institutions of higher education Native American tribal governments (Federally recognized) Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses City or township governments Public housing authorities/Indian housing authorities For profit organizations other than small businesses Public and State controlled institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) State governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Purpose. The goal of this Funding Opportunity Announcement (FOA) issued by the National Institute of Allergy and Infectious Diseases (NIAID) is to facilitate the translation of innovative and promising basic science-derived vaccine concepts for prophylactic HIV vaccines to initial clinical trials by providing the critical resources necessary for achieving this goal. The Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) is a mechanism that enables investigators to conduct clinical research studies aimed at addressing specific scientific questions and vaccine concepts most appropriately tested in humans. To fulfill this goal, an IPCAVD award is intended to provide assistance to meritorious competitive projects in 3 areas: (1) support for basic hypothesis-driven science to advance development of the vaccine concept by facilitating non-human primate (NHP) proof-of-concept studies and down-selection to the best lead candidate; (2) access to resources for determining whether the vaccine concept is clinically feasible by determining whether a candidate vaccine successfully addresses FDA requirements for performing clinical testing, by determining the feasibility of manufacturing cGMP lots of the vaccine and by determining vaccine safety by conducting the required toxicology and pharmacology safety studies; and (3) support for the initial human clinical study central to addressing the proposed scientific question. A preclinical research project application alone is not appropriate for this announcement. Mechanism of Support. This FOA will utilize the multi-project Cooperative Agreement (U19) award mechanism. Funds Available and Anticipated Number of Awards. NIAID anticipates that approximately $3.2 million total costs will be available in FY2011 to fund 1-2 new or renewal wards in response to this FOA. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-10-161.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| Modified Archive Date based on new Expiration Date, per NOT-AI-11-043. | Apr 19, 2011 | |
| This PAR was updated to reflect changes in the close date and archive date. | Apr 19, 2011 | |
| Mar 31, 2010 |
DISPLAYING: Synopsis 3
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-10-161 |
| Funding Opportunity Title: | Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.855 — Allergy, Immunology and Transplantation Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 3 |
| Posted Date: | Mar 30, 2010 |
| Last Updated Date: | Apr 19, 2011 |
| Original Closing Date for Applications: | Aug 02, 2012 |
| Current Closing Date for Applications: | Nov 08, 2011 |
| Archive Date: | Dec 08, 2011 |
| Estimated Total Program Funding: | $3,200,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Independent school districts County governments Private institutions of higher education Native American tribal governments (Federally recognized) Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses City or township governments Public housing authorities/Indian housing authorities For profit organizations other than small businesses Public and State controlled institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) State governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Purpose. The goal of this Funding Opportunity Announcement (FOA) issued by the National Institute of Allergy and Infectious Diseases (NIAID) is to facilitate the translation of innovative and promising basic science-derived vaccine concepts for prophylactic HIV vaccines to initial clinical trials by providing the critical resources necessary for achieving this goal. The Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) is a mechanism that enables investigators to conduct clinical research studies aimed at addressing specific scientific questions and vaccine concepts most appropriately tested in humans. To fulfill this goal, an IPCAVD award is intended to provide assistance to meritorious competitive projects in 3 areas: (1) support for basic hypothesis-driven science to advance development of the vaccine concept by facilitating non-human primate (NHP) proof-of-concept studies and down-selection to the best lead candidate; (2) access to resources for determining whether the vaccine concept is clinically feasible by determining whether a candidate vaccine successfully addresses FDA requirements for performing clinical testing, by determining the feasibility of manufacturing cGMP lots of the vaccine and by determining vaccine safety by conducting the required toxicology and pharmacology safety studies; and (3) support for the initial human clinical study central to addressing the proposed scientific question. A preclinical research project application alone is not appropriate for this announcement. Mechanism of Support. This FOA will utilize the multi-project Cooperative Agreement (U19) award mechanism. Funds Available and Anticipated Number of Awards. NIAID anticipates that approximately $3.2 million total costs will be available in FY2011 to fund 1-2 new or renewal wards in response to this FOA. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-10-161.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-10-161 |
| Funding Opportunity Title: | Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.855 — Allergy, Immunology and Transplantation Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Apr 19, 2011 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Nov 08, 2012 |
| Archive Date: | Dec 08, 2012 |
| Estimated Total Program Funding: | $3,200,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | For profit organizations other than small businesses City or township governments Public housing authorities/Indian housing authorities Others (see text field entitled “Additional Information on Eligibility” for clarification) Independent school districts Native American tribal governments (Federally recognized) Private institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments State governments Small businesses Public and State controlled institutions of higher education Special district governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Purpose. The goal of this Funding Opportunity Announcement (FOA) issued by the National Institute of Allergy and Infectious Diseases (NIAID) is to facilitate the translation of innovative and promising basic science-derived vaccine concepts for prophylactic HIV vaccines to initial clinical trials by providing the critical resources necessary for achieving this goal. The Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) is a mechanism that enables investigators to conduct clinical research studies aimed at addressing specific scientific questions and vaccine concepts most appropriately tested in humans. To fulfill this goal, an IPCAVD award is intended to provide assistance to meritorious competitive projects in 3 areas: (1) support for basic hypothesis-driven science to advance development of the vaccine concept by facilitating non-human primate (NHP) proof-of-concept studies and down-selection to the best lead candidate; (2) access to resources for determining whether the vaccine concept is clinically feasible by determining whether a candidate vaccine successfully addresses FDA requirements for performing clinical testing, by determining the feasibility of manufacturing cGMP lots of the vaccine and by determining vaccine safety by conducting the required toxicology and pharmacology safety studies; and (3) support for the initial human clinical study central to addressing the proposed scientific question. A preclinical research project application alone is not appropriate for this announcement. Mechanism of Support. This FOA will utilize the multi-project Cooperative Agreement (U19) award mechanism. Funds Available and Anticipated Number of Awards. NIAID anticipates that approximately $3.2 million total costs will be available in FY2011 to fund 1-2 new or renewal wards in response to this FOA. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-10-161.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-10-161 |
| Funding Opportunity Title: | Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) (U19) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.855 — Allergy, Immunology and Transplantation Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Mar 31, 2010 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Aug 02, 2012 |
| Archive Date: | Sep 02, 2012 |
| Estimated Total Program Funding: | $3,200,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | For profit organizations other than small businesses City or township governments Public housing authorities/Indian housing authorities Others (see text field entitled “Additional Information on Eligibility” for clarification) Independent school districts Native American tribal governments (Federally recognized) Private institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments State governments Small businesses Public and State controlled institutions of higher education Special district governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Purpose. The goal of this Funding Opportunity Announcement (FOA) issued by the National Institute of Allergy and Infectious Diseases (NIAID) is to facilitate the translation of innovative and promising basic science-derived vaccine concepts for prophylactic HIV vaccines to initial clinical trials by providing the critical resources necessary for achieving this goal. The Integrated Preclinical/Clinical AIDS Vaccine Development Program (IPCAVD) is a mechanism that enables investigators to conduct clinical research studies aimed at addressing specific scientific questions and vaccine concepts most appropriately tested in humans. To fulfill this goal, an IPCAVD award is intended to provide assistance to meritorious competitive projects in 3 areas: (1) support for basic hypothesis-driven science to advance development of the vaccine concept by facilitating non-human primate (NHP) proof-of-concept studies and down-selection to the best lead candidate; (2) access to resources for determining whether the vaccine concept is clinically feasible by determining whether a candidate vaccine successfully addresses FDA requirements for performing clinical testing, by determining the feasibility of manufacturing cGMP lots of the vaccine and by determining vaccine safety by conducting the required toxicology and pharmacology safety studies; and (3) support for the initial human clinical study central to addressing the proposed scientific question. A preclinical research project application alone is not appropriate for this announcement. Mechanism of Support. This FOA will utilize the multi-project Cooperative Agreement (U19) award mechanism. Funds Available and Anticipated Number of Awards. NIAID anticipates that approximately $3.2 million total costs will be available in FY2011 to fund 1-2 new or renewal wards in response to this FOA. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-10-161.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Related Documents
There are no related documents on this grant.
Packages
There are no packages on this grant.
Share This Post, Choose Your Platform!
About the Author: osnqt
